PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Inclusion Criteria:

Patients eligible for inclusion in this study have to meet all of the following criteria:

- Patient must have had at least one prior line of therapy for their disease and must
not be beyond 4th progression/relapse of disease (5 maximum prior lines).

- Patient has a pathology confirmed diagnosis of a solid tumor or lymphoma listed in the
section "condition". Patients must have measurable disease as per appropriate
guidelines (Solid Tumors by RECIST 1.1 and Diffuse Large B-cell Lymphoma by Revised
Response Criteria for Malignant Lymphoma - Cheson et al 2007).

- Expansion Cohorts only: Patient must have a site of disease amenable to biopsy, and be
a candidate for tumor biopsy according to the treating institution's guidelines.
Exceptions may be considered after discussion with the sponsor.

Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

- History of severe hypersensitivity reactions to other mAbs.

- Impaired cardiac function or clinically significant cardiac disease.

- Active, known or suspected autoimmune disease or a documented history of autoimmune
disease within three years prior to screening with a few exceptions as per protocol.

- Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated
for skin rash or with replacement therapy for endocrinopathies should not be excluded.

- Patient with second primary malignancy within < 3 years of first dose of study
treatment.

- Prior immunotherapy treatment with PD-1, PD-L1, CTLA-4, or LAG-3 antibodies.

Other protocol-defined inclusion/exclusion criteria may apply.